WO2002080899A1 - Agent de traitement de maladie digestive - Google Patents

Agent de traitement de maladie digestive Download PDF

Info

Publication number
WO2002080899A1
WO2002080899A1 PCT/JP2002/003006 JP0203006W WO02080899A1 WO 2002080899 A1 WO2002080899 A1 WO 2002080899A1 JP 0203006 W JP0203006 W JP 0203006W WO 02080899 A1 WO02080899 A1 WO 02080899A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkylene
hydrocarbon group
digestive disease
aromatic hydrocarbon
remedial agent
Prior art date
Application number
PCT/JP2002/003006
Other languages
English (en)
Japanese (ja)
Inventor
Tatsuo Horizoe
Masanobu Shinoda
Eita Emori
Fumiyoshi Matsuura
Toshihiko Kaneko
Norihito Ohi
Shunji Kasai
Hideki Yoshitomi
Kazuto Yamazaki
Sadakazu Miyashita
Taro Hihara
Takashi Seiki
Richard Clark
Hitoshi Harada
Original Assignee
Eisai Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co., Ltd. filed Critical Eisai Co., Ltd.
Priority to JP2002578938A priority Critical patent/JPWO2002080899A1/ja
Publication of WO2002080899A1 publication Critical patent/WO2002080899A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un médicament, notamment pour la prévention/le traitement des maladies digestives, contenant en tant que principe actif un nouveau dérivé de l'acide carboxylique correspondant à la formule (I), dans laquelle R1 représente l'hydrogène, etc.; L représente alcoylène, etc.; M représente alcoylène, etc.; T représente alcoylène, etc.; W représente carboxyle, etc.;----- représente une simple liaison ou une double liaison; X représente l'oxygène, etc.; Y représente une groupe hydrocarboné aromatique, etc.; et le noyau Z représente un groupe hydrocarboné aromatique en C¿5?-C6, ainsi qu'un sel du dérivé, ou un hydrate de l'un ou de l'autre.
PCT/JP2002/003006 2001-03-30 2002-03-27 Agent de traitement de maladie digestive WO2002080899A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002578938A JPWO2002080899A1 (ja) 2001-03-30 2002-03-27 消化器疾患治療剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-101465 2001-03-30
JP2001101465 2001-03-30
JP2001105131 2001-04-03
JP2001-105131 2001-04-03

Publications (1)

Publication Number Publication Date
WO2002080899A1 true WO2002080899A1 (fr) 2002-10-17

Family

ID=26612853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/003006 WO2002080899A1 (fr) 2001-03-30 2002-03-27 Agent de traitement de maladie digestive

Country Status (2)

Country Link
JP (1) JPWO2002080899A1 (fr)
WO (1) WO2002080899A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100813A2 (fr) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulateurs de recepteurs actives par le proliferateur de peroxysome
EP1348698A4 (fr) * 2000-12-05 2005-01-19 Kyorin Seiyaku Kk Derives de l'acide carboxylique substitues
US7244861B2 (en) 2001-03-30 2007-07-17 Eisai Co., Ltd. Benzene compound and salt thereof
WO2008004341A1 (fr) * 2006-07-03 2008-01-10 The University Of Tokyo DÉRIVÉS DE L'ACIDE PHÉNYLPROPIONIQUE SUBSTITUÉS EN α
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
US7544835B2 (en) 2001-04-20 2009-06-09 Eisai R&D Management Co., Ltd. Carboxylic acid derivative and salt thereof
JP2009522255A (ja) * 2005-12-30 2009-06-11 エスケー ホルディングス カンパニー リミテッド イソキサゾール誘導体及びその使用
WO2010058858A1 (fr) * 2008-11-21 2010-05-27 ラクオリア創薬株式会社 Nouveau dérivé de pyrazole-3-carboxamide doté d’une activité antagoniste du récepteur 5-ht2b
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
JP2014532054A (ja) * 2011-09-30 2014-12-04 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
US9394287B2 (en) 2010-11-05 2016-07-19 Senomyx, Inc. Compounds useful as modulators of TRPM8
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9701674B2 (en) 2008-12-19 2017-07-11 Vertex Pharmaceuticals Incorporated Substituted pyrazines as ATR kinase inhibitors
US9732071B2 (en) 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8
US9791456B2 (en) 2012-10-04 2017-10-17 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US10144731B2 (en) 2013-12-18 2018-12-04 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US10272095B2 (en) 2015-06-15 2019-04-30 GlaxoSmithKline Intellectual Propert Development Limited NRF2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US10478430B2 (en) 2012-04-05 2019-11-19 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US10604509B2 (en) 2015-06-15 2020-03-31 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
JP2020514364A (ja) * 2017-03-14 2020-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｈｇｄｈ阻害薬としてのトシルアセタートベース化合物及びその誘導体
WO2020153414A1 (fr) 2019-01-24 2020-07-30 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
US10813929B2 (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating cancer with ATR inhibitors
CN113717045A (zh) * 2021-10-11 2021-11-30 梧州学院 一种对羟基苯甲酸铜(ii)配合物及其合成方法和应用
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043081A1 (fr) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Traitement de troubles gastro-intestinaux au moyen de modulateurs du recepteur active de la proliferation des peroxysomes (ppar)
WO2000075103A1 (fr) * 1999-06-09 2000-12-14 Kyorin Pharmaceutical Co., Ltd. DERIVES D'ACIDE PHENYLPROPIONIQUE SUBSTITUES COMME AGONISTES DU RECEPTEUR HUMAIN ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR) $g(a)
WO2001021578A1 (fr) * 1999-09-17 2001-03-29 Kyorin Pharmaceutical Co., Ltd. Derives d'o-anisamide
WO2001025181A1 (fr) * 1999-10-01 2001-04-12 Eisai Co., Ltd. Derives d'acide carboxylique et medicaments les contenant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043081A1 (fr) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Traitement de troubles gastro-intestinaux au moyen de modulateurs du recepteur active de la proliferation des peroxysomes (ppar)
WO2000075103A1 (fr) * 1999-06-09 2000-12-14 Kyorin Pharmaceutical Co., Ltd. DERIVES D'ACIDE PHENYLPROPIONIQUE SUBSTITUES COMME AGONISTES DU RECEPTEUR HUMAIN ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR) $g(a)
WO2001021578A1 (fr) * 1999-09-17 2001-03-29 Kyorin Pharmaceutical Co., Ltd. Derives d'o-anisamide
WO2001025181A1 (fr) * 1999-10-01 2001-04-12 Eisai Co., Ltd. Derives d'acide carboxylique et medicaments les contenant

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348698A4 (fr) * 2000-12-05 2005-01-19 Kyorin Seiyaku Kk Derives de l'acide carboxylique substitues
US7244861B2 (en) 2001-03-30 2007-07-17 Eisai Co., Ltd. Benzene compound and salt thereof
EP1375472A4 (fr) * 2001-03-30 2008-12-10 Eisai R&D Man Co Ltd Compose de benzene et sel de ce compose
US7544835B2 (en) 2001-04-20 2009-06-09 Eisai R&D Management Co., Ltd. Carboxylic acid derivative and salt thereof
WO2002100813A3 (fr) * 2001-06-07 2003-11-27 Lilly Co Eli Modulateurs de recepteurs actives par le proliferateur de peroxysome
WO2002100813A2 (fr) * 2001-06-07 2002-12-19 Eli Lilly And Company Modulateurs de recepteurs actives par le proliferateur de peroxysome
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US8426473B2 (en) 2005-06-30 2013-04-23 High Point Pharnaceuticals, LLC Phenoxy acetic acids as PPAR delta activators
US8217086B2 (en) 2005-06-30 2012-07-10 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8551993B2 (en) 2005-12-22 2013-10-08 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US9855274B2 (en) 2005-12-22 2018-01-02 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US10471066B2 (en) 2005-12-22 2019-11-12 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US9663481B2 (en) 2005-12-22 2017-05-30 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists
US10947180B2 (en) 2005-12-22 2021-03-16 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US11420929B2 (en) 2005-12-22 2022-08-23 Vtv Therapeutics Llc Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists
US8362016B2 (en) 2005-12-22 2013-01-29 High Point Pharmaceuticals, Llc Phenyl propionic acids as PPAR delta activators
JP2009522255A (ja) * 2005-12-30 2009-06-11 エスケー ホルディングス カンパニー リミテッド イソキサゾール誘導体及びその使用
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
JPWO2008004341A1 (ja) * 2006-07-03 2009-12-03 国立大学法人 東京大学 α−置換フェニルプロピオン酸誘導体
JP5147071B2 (ja) * 2006-07-03 2013-02-20 国立大学法人 東京大学 α−置換フェニルプロピオン酸誘導体
WO2008004341A1 (fr) * 2006-07-03 2008-01-10 The University Of Tokyo DÉRIVÉS DE L'ACIDE PHÉNYLPROPIONIQUE SUBSTITUÉS EN α
JP5621148B2 (ja) * 2008-11-21 2014-11-05 ラクオリア創薬株式会社 ５−ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール−３−カルボキサミド誘導体
US8252790B2 (en) 2008-11-21 2012-08-28 Raqualia Pharma Inc. Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity
KR101637337B1 (ko) 2008-11-21 2016-07-07 라퀄리아 파마 인코포레이티드 5-ｈｔ2ｂ 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체
WO2010058858A1 (fr) * 2008-11-21 2010-05-27 ラクオリア創薬株式会社 Nouveau dérivé de pyrazole-3-carboxamide doté d’une activité antagoniste du récepteur 5-ht2b
CN102224142A (zh) * 2008-11-21 2011-10-19 拉夸里亚创药株式会社 具有5-ht2b受体拮抗活性的新型吡唑-3-羧酰胺衍生物
KR20110091550A (ko) * 2008-11-21 2011-08-11 라퀄리아 파마 인코포레이티드 5-ｈｔ2ｂ 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체
US10479784B2 (en) 2008-12-19 2019-11-19 Vertex Pharmaceuticals Incorporated Substituted pyrazin-2-amines as inhibitors of ATR kinase
US9701674B2 (en) 2008-12-19 2017-07-11 Vertex Pharmaceuticals Incorporated Substituted pyrazines as ATR kinase inhibitors
US10961232B2 (en) 2008-12-19 2021-03-30 Vertex Pharmaceuticals Incorporated Substituted pyrazines as ATR kinase inhibitors
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US10953007B2 (en) 2010-11-05 2021-03-23 Firmenich Incorporated Compounds useful as modulators of TRPM8
US9394287B2 (en) 2010-11-05 2016-07-19 Senomyx, Inc. Compounds useful as modulators of TRPM8
US10016418B2 (en) 2010-11-05 2018-07-10 Seaomyx, Inc. Compounds useful as modulators of TRPM8
US10208027B2 (en) 2011-09-30 2019-02-19 Vertex Pharmaceuticals Incorporated Processes for preparing ATR inhibitors
JP2014532054A (ja) * 2011-09-30 2014-12-04 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
US9862709B2 (en) 2011-09-30 2018-01-09 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
US10822331B2 (en) 2011-09-30 2020-11-03 Vertex Pharmaceuticals Incorporated Processes for preparing ATR inhibitors
JP2017226676A (ja) * 2011-09-30 2017-12-28 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
US10813929B2 (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating cancer with ATR inhibitors
US10478430B2 (en) 2012-04-05 2019-11-19 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US11110086B2 (en) 2012-04-05 2021-09-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase and combination therapies thereof
US9791456B2 (en) 2012-10-04 2017-10-17 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US10144731B2 (en) 2013-12-18 2018-12-04 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US10604509B2 (en) 2015-06-15 2020-03-31 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US10485806B2 (en) 2015-06-15 2019-11-26 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US10272095B2 (en) 2015-06-15 2019-04-30 GlaxoSmithKline Intellectual Propert Development Limited NRF2 regulators
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US9732071B2 (en) 2015-10-01 2017-08-15 Senomyx, Inc. Compounds useful as modulators of TRPM8
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US11304929B2 (en) 2017-03-14 2022-04-19 Boehringer Ingelheim International Gmbh Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors
JP2020514364A (ja) * 2017-03-14 2020-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｈｇｄｈ阻害薬としてのトシルアセタートベース化合物及びその誘導体
WO2020153414A1 (fr) 2019-01-24 2020-07-30 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
CN113717045A (zh) * 2021-10-11 2021-11-30 梧州学院 一种对羟基苯甲酸铜(ii)配合物及其合成方法和应用

Also Published As

Publication number Publication date
JPWO2002080899A1 (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2002080899A1 (fr) Agent de traitement de maladie digestive
WO2004056828A3 (fr) Nouveaux composes et leur utilisation
EP1076055A4 (fr) Derives de 1- (1-substituee-4-piperidinyle)methyle]-4-piperidine, procede de production de ceux-ci, compositions medicinales contenant ces composes et intermediaires de ces composes
WO2002100812A1 (fr) Dérivé de l'acide carboxylique et son sel
EP1535915A4 (fr) Derive de furane ou de thiophene, et ses utilisations pharmaceutiques
AU7961100A (en) Drug discharge pump inhibitors
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
EP1847263A3 (fr) Inhibiteurs de production et de libération de cytokines inflammatoires
NO20074012L (no) 1-tio-D-glucitolderivater
AU2002239344A1 (en) Pyrazolopyridines
CY1110593T1 (el) Η χρηση φαρμακευτικης συνθεσης που περιεχει παραγωγο παρα - αμινοφαινυλοξικου οξεος για τη θεραπεια των φλεγμονωδων καταστασεων του γαστρεντερικου σωληνα
EP1374679A3 (fr) Composition stérilisante et procédé de stérilisation utilisant celle-ci
DE50010886D1 (de) Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
NO20071321L (no) Anti-inflammatoriske midler
WO2002092072A3 (fr) Medicaments contre la maladie d'alzheimer
NO20044449L (no) Salter av tolterodin
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
WO2003008380A1 (fr) Derives d'acide carboxylique
WO2002024697A1 (fr) Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif
EP1491187A4 (fr) Agent prophylactique ou therapeutique contre des maladies renales
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
WO2003066594A3 (fr) Inhibiteurs de l'integrine $g(a)v$g(b)6
EP1374868A4 (fr) Remedes et/ou medicaments preventifs pour des cardiopathies ischemiques diabetiques
EP1391452A4 (fr) Derive de 4-hydroxypiperidine a activite analgesique
DK0855397T3 (da) (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002578938

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase